AcelRx commences dosing in second ARX-01 Phase 3 clinical trial for acute post-operative pain AcelRx Pharmaceuticals, Inc. Related StoriesInner ear damage mind warnings from nerve cellsDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of PolyphotonixImmune submits Bertilimumab IND software to FDA for treatment of Bullous PemphigoidIn March 2012, AcelRx initiated its first Phase 3 medical study for ARX-01, a randomized, double-blind, placebo-controlled safety and efficacy study comparing ARX-01 to placebo for post-operative pain control subsequent major open abdominal surgery levitra 20 .
By formulating amlexanox in its proprietary mucoadhesive polymer hydrogel delivery system, Access includes a protectable and patented formulation of the interesting pharmaceutical active. Davis, CEO and President of Gain access to Pharmaceuticals, Inc. We believe a proprietary formulation of amlexanox, within an easy to use format, could have broad clinical applications and industrial appeal. Amlexanox provides been shown to be as effective as dexamethasone in treatment of erosive oral lichen planus. Barrett's esophagus is a pre-cancerous condition regarded as due to chronic acid publicity from reflux esophagitis, and is estimated to be there in 10 percent to 20 percent of individuals with gastroesophageal reflux disease ..